Accredited Educational Activities

New Insights on the Diagnosis and Treatment of Nonproliferative Diabetic Retinopathy

This enduring program targets critical issues in nonproliferative diabetic retinopathy (NPDR), including risk for retinopathy development and progression, how early treatment can help prevent progression to vision-threatening complications, and treatment strategies for NPDR. Learn essential elements of assessment and management, as well as clinical trial data on the latest approaches in care, helping to preserve vision in diabetes.

A Close Look at the Diagnosis and Treatment of Patients with Retinal Vascular Disease

This online activity targets healthcare gaps related to the diagnosis and management of diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO), impacting outcomes through risk stratification, diagnostic strategies, and treatment individualization with anti-VEGF agents.

CLICK ON STATES TO SEE LIVE ACTIVITIES

ONLINE ACTIVITIES

Jun
17
Wed
Seeing New Possibilities in Retinal Disease: Anti-VEGF Therapies and Beyond
Jun 17 2020 @ 8:00 am – Oct 1 2022 @ 9:00 am

Seeing New Possibilities in Retinal Disease: Anti-VEGF Therapies and Beyond

View Activity

FACULTY

Dilsher Dhoot, MD
California Retina Consultants
Adjunct Clinical Assistant Professor of Ophthalmology
Keck School of Medicine (USC)
Santa Barbara, CA

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to the recognition, prevention, and management of diabetic retinopathy (DR). An expert panel discussion will guide you in identifying candidates for anti-VEGF therapy, review clinical trial data on the use of these agents, and provide evidence-based strategies to individualize the management of DR and overcome treatment barriers.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Integrate evidence-based prevention, diagnostic, and treatment strategies for retinal disease into clinical workflow
  • Identify patients with diabetic retinopathy (DR), who would benefit from anti-vascular endothelial growth factor therapy (anti-VEGF) therapy
  • Explain the rationale for intervening early in the disease process when treating patients with DR

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy. CNE Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucci, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

Dilsher Dhoot, MD discloses the following financial interests or relationships:

  • Consultant: Allergan, Alimera, Bayer, Eyepoint, Genentech, Regenex, Regeneron, Novartis
  • Speakers’ Bureau: Alimera, Eyepoint, Genentech, Regeneron, Novartis

CME Content Review

The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Nicole Longo, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Diana Tommasi, Medical Director of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Scroll to Top

Search

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for diabetic retinopathy (DR) in patients with diabetes who have or are at risk for developing DR. Click on one of the options below to learn more about DR.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | Diabetic Retinopathy | All Rights Reserved | Website by Divigner
Menu

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX